Drug evaluation: TG-1042, an adenovirus-mediated IFNγ gene delivery for the intratumoral therapy of primary cutaneous lymphomas

Current Opinion in Investigational Drugs

Volumn 8, Issue 6, 2007, Pages 493-498

  Urosevic, Mirjana ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; TG 1042; UNCLASSIFIED DRUG;

ADENOVIRUS; B CELL LYMPHOMA; CLINICAL TRIAL; COLITIS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SYNTHESIS; FATIGUE; FEVER; FLU LIKE SYNDROME; GENE DELIVERY SYSTEM; HUMAN; INJECTION SITE BURNING; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE REACTION; LUNG METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; REVIEW; SINGLE DRUG DOSE; SKIN LYMPHOMA; STRUCTURE ACTIVITY RELATION; T CELL LYMPHOMA; VOMITING;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; GENE THERAPY; HUMANS; INTERFERON TYPE II; LYMPHOMA, T-CELL, CUTANEOUS; SKIN NEOPLASMS;

EID: 34249877414     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. 392566 New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Fallaux FJ, Bout A, Van Der Velde I, Van Den Wollenberg DJ, Hehir KM, Keegan J, Auger C, Cramer SJ, Van Ormondt H, Van Der Eb AJ, Valerio D et al HUM GENE THER 1998 9 13 1909-1917
2. 412720 Immunotherapy of cancer with adenovirus vectors expressing interleukin-2 or interferon-γ. Malarme D MOL THER 2001 3 5 Pt II Abs 1077
3. 493172 Transgene presents positive phase I/II data on its adeno-interferon γ product in cutaneous lymphoma at the American Society of Gene Therapy Meeting. Transgene SA PRESS RELEASE 2003 June 11
4. 498681 Transgene's adeno-IFNγ product candidate receives Orphan Drug designation in Europe. Transgene SA PRESS RELEASE 2003 July 23
5. 530513 Intra-tumoral delivery of TG1024 (adenovirus-interleukin-2) or TG1042 (adenovirus-interferon-γ) in combination with systemic chemotherapy: Pre-clinical studies in murine models. Slos P, De Meyer M, Bleuzen P, Acres B, Squiban P, Urosevic M PROC AM ASSOC CANCER RES 2004 45 Abs 4605
6. 565087 Gene-based vaccines and immunotherapeutics. Liu M, Acres B, Balloul JM, Bizouarne N, Paul S, Slos P, Squiban P PROC NATL ACAD SCI USA 2004 101 Suppl 2 14567-14571
7. 586504 Transgene: New strategy in therapeutic vaccines, MVA-Muc1-IL2 meets primary endpoint in lung cancer phase II. Transgene SA PRESS RELEASE 2005 February 23
8. 614302 Adenovirus-mediated intralesional interferon-γ gene transfer induces tumor regressions in cutaneous lymphomas. Dummer R, Hassel H, Fellenberg F, Eichmuller S, Maier T, Slos P, Acres B, Bleuzen P, Bataille V, Squiban P, Burg G et al BLOOD 2004 104 6 1631-1638
9. 614303 Tumor irradiation followed by intratumoral cytokine gene therapy for murine renal adenocarcinoma. Hillman GG, Slos P, Wang Y, Wright JL, Layer A, De Meyer M, Yudelev M, Che M, Forman JD CANCER GENE THER 2004 11 1 61-72
10. 614333 Drug Development pipeline: TG-1042. Transgene SA COMPANY COMMUNICATION 2005 July 26
11. 614342 A phase I trial of immunotherapy with intratumoral adenovirus-interferon-γ (TG1041) in patients with malignant melanoma. Khorana AA, Rosenblatt JD, Sahasrabudhe DM, Evans T, Ladrigan M, Marquis D, Rosell K, Whiteside T, Phillippe S, Acres B, Slos P et al CANCER GENE THER 2003 10 4 251-259
12. 638738 Adenovirus-interferon-γ (TG1042) demonstates clinical activity in relapsing primary cutaneous lymphoma (PCL): A phase I/II multicentric trial. Urosevic M, Luger TE, Sterry W, Dreno B, Dereure O, Baudard M, Bagot M, Bleuzen P, Rossi J-F, Dummer R BLOOD 2005 106 11 Abs 1497
13. 658455 Product pipeline: TG 1042 (Ad-IFNγ). Transgene SA COMPANY WORLD WIDE WEB SITE 2006 June 30
14. 671209 Adenovirus-interferon γ (TG1042) demonstrates good tolerance and efficacy in relapsing primary cutaneous lymphoma (PCL): Final results of a phase I/II multicentric trial. Urosevic M PROC AM SOC CLIN ONCOL 2006 25 Abs 7539
15. 730045 Transgene: Net cash expenditures and cash position as of September 30, 2006. Transgene SA PRESS RELEASE 2006 October 11
16. 768598 Standard and experimental therapy in cutaneous T-cell lymphomas. Dummer R, Cozzio A, Meier S, Beyeler M, Laetsch B, Doebbeling U, Urosevic M J CUTANEOUS PATHOL 2006 33 Suppl 1 52-57
17. 768646 Pathogenesis and therapy of cutaneous lymphomas - progress or impasse? Dummer R, Cozzio A, Urosevic M EXP DERMATOL 2006 15 5 392-400
18. 768648 Good manufacturing practice production of adenoviral vectors for clinical trials. Lusky M HUM GENE THER 2005 16 3 281-291
19. 768649 Interferons, immunity and cancer immunoediting. Dunn GP, Koebel CM, Schreiber RD NAT REV IMMUNOL 2006 6 11 836-848
20. 769278 NCT00394693: Study to evaluate the safety and efficacy of adeno-IFNγ in cutaneous B-cell lymphoma. Transgene CLINICALTRIALS.GOV 2007 February 23
21. 769909 Transgene - immunotherapy to fight cancer and infectious diseases. Transgene SA COMPANY WORLD WIDE WEB SITE 2007 February 01
22. 774445 Transgene: First patients included in TG 1042 (Ad-IFNγ) phase II clinical trial in cutaneous B-cell lymphoma. Transgene SA PRESS RELEASE 2007 March 14
23. 781462 Cancer surveillance series: Non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. Groves FD, Linet MS, Travis LB, Devesa SS J NATL CANCER INST 2000 92 15 1240-1251
24. 785559 Cytokines in cancer immunity and immunotherapy. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y IMMUNOL REV 2004 202 275-293
25. 785560 Second-generation interferons for cancer: Clinical targets. Borden EC, Lindner D, Dreicer R, Hussein M, Peereboom D SEMIN CANCER BIOL 2000 10 2 125-144
26. 785565 Intra-lesional low-dose interferon ?2a therapy for primary cutaneous marginal zone B-cell lymphoma. Cozzio A, Kempf W, Schmid-Meyer R, Gilliet M, Michaelis S, Scharer L, Burg G, Dummer R LEUK LYMPHOMA 2006 47 5 865-869
27. 785571 Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: Report and follow-up of eight cases. Kerl K, Prins C, Saurat JH, French LE BR J DERMATOL 2006 155 6 1197-1200
28. 785575 Cutaneous B-cell lymphoma responds to rituximab: A report of five cases and a review of the literature. Gitelson E, Al-Saleem T, Millenson M, Lessin S, Smith MR LEUK LYMPHOMA 2009 47 9 1902-1907
29. 785576 Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Heinzerling LM, Urbanek M, Funk JO, Peker S, Bleck O, Neuber K, Burg G, von Den Driesch P, Dummer R CANCER 2000 89 8 1835-1844
30. 785620 Cutaneous lymphomas. Burg G, Kempf W, Haeffner AC CURR PROBL DERMATOL 1997 9 5 137-204
31. 786820 Final results of a phase I/II multicentric trial of adenovirus-IFN-γ (TG1042) demonstrate good tolerance and efficacy in relapsing primary cutaneous lymphoma (PCL). Urosevic M, Dreno B, Assaf C, Schiller M, Dereure O, Baudard M, Bagot M, Khammari A, Bataille V, Bleuzen P, Dummer R J INVEST DERMATOL 2006 126 Suppl 2 S29
32. 787920 Phase I/II trial design: TG-1042. University Hospital Zurich COMPANY COMMUNICATION 2007 April 27